Srinivas Akkaraju, MD, PhD
Srini Akkaraju has over 16 years of investment and operational experience in the life sciences sector. He joined Sofinnova in 2013 as a General Partner, and concentrates on biopharmaceuticals investments. Srini’s board memberships have included Piramed (acquired by Roche), Eyetech Pharmaceuticals (EYET), Synageva BioPharma (GEVA), Seattle Genetics (SGEN),Intercept Pharmaceuticals, (ICPT), Ophthotech and Versartis.
Most recently, Srini was a Managing Director at New Leaf Venture Partners. Prior to NLVP, he was a co-founder and Managing Director at Panorama Capital. Before forming Panorama, he served as Partner of J.P. Morgan Partners. Prior to J.P. Morgan Partners, Srini held business and corporate development positions at Genentech. He received B.A. degrees in both Biochemistry and Computer Science from Rice University and M.D. and Ph.D. degrees in Immunology from Stanford University School of Medicine.
Assistant: Tiffany Davis. Email: tiffany(at)sofinnova.com.